XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK-BASED COMPENSATION (Tables)
9 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation Expense and Resulting Tax Benefits
Stock-based compensation expense and the resulting deferred tax benefits were as follows (in thousands):
Three Months Ended March 31,Nine Months Ended March 31,
2023202220232022
Pre-tax stock-based compensation expense$6,560 $14,004 $16,375 $37,792 
Less: deferred tax benefit (a)
2,400 3,288 4,407 8,013 
Total stock-based compensation expense, net of tax$4,160 $10,716 $11,968 $29,779 
_________________________________
(a)For the three and nine months ended March 31, 2023, the deferred tax benefit was reduced by $0.7 million and $0.2 million, respectively, attributable to stock-based compensation expense that is nondeductible for tax purposes pursuant to Section 162(m) as amended by the Tax Cuts and Jobs Act of 2017.
Schedule of Information Related to Restricted Stock
The following table includes information related to restricted stock, performance share awards and stock options for the nine months ended March 31, 2023:
Restricted StockPerformance Share AwardsStock Options
Number of AwardsWeighted Average Fair Value at Grant DateNumber of AwardsWeighted Average Fair Value at Grant DateNumber of OptionsWeighted Average Exercise Price
Outstanding at June 30, 20221,201,130 $35.59 1,578,795 $33.66 896,354 $30.38 
Granted419,519 36.69 823,009 35.34 — — 
Vested/exercised(257,571)36.37 (826,743)36.35 (24,351)32.84 
Forfeited(72,268)35.81 (81,350)33.41 (2,906)35.65 
Outstanding at March 31, 20231,290,810 $35.78 1,493,711 $33.09 869,097 $30.30 
Stock options outstanding and exercisable at March 31, 2023869,097 $30.30 
Schedule of Information Related to Performance Share Awards
The following table includes information related to restricted stock, performance share awards and stock options for the nine months ended March 31, 2023:
Restricted StockPerformance Share AwardsStock Options
Number of AwardsWeighted Average Fair Value at Grant DateNumber of AwardsWeighted Average Fair Value at Grant DateNumber of OptionsWeighted Average Exercise Price
Outstanding at June 30, 20221,201,130 $35.59 1,578,795 $33.66 896,354 $30.38 
Granted419,519 36.69 823,009 35.34 — — 
Vested/exercised(257,571)36.37 (826,743)36.35 (24,351)32.84 
Forfeited(72,268)35.81 (81,350)33.41 (2,906)35.65 
Outstanding at March 31, 20231,290,810 $35.78 1,493,711 $33.09 869,097 $30.30 
Stock options outstanding and exercisable at March 31, 2023869,097 $30.30 
Schedule of Information Related to Stock Options
The following table includes information related to restricted stock, performance share awards and stock options for the nine months ended March 31, 2023:
Restricted StockPerformance Share AwardsStock Options
Number of AwardsWeighted Average Fair Value at Grant DateNumber of AwardsWeighted Average Fair Value at Grant DateNumber of OptionsWeighted Average Exercise Price
Outstanding at June 30, 20221,201,130 $35.59 1,578,795 $33.66 896,354 $30.38 
Granted419,519 36.69 823,009 35.34 — — 
Vested/exercised(257,571)36.37 (826,743)36.35 (24,351)32.84 
Forfeited(72,268)35.81 (81,350)33.41 (2,906)35.65 
Outstanding at March 31, 20231,290,810 $35.78 1,493,711 $33.09 869,097 $30.30 
Stock options outstanding and exercisable at March 31, 2023869,097 $30.30 
Schedule of Unrecognized Stock-Based Compensation Expense
Unrecognized stock-based compensation expense at March 31, 2023 was as follows (in thousands):
Unrecognized Stock-Based Compensation ExpenseWeighted Average Amortization Period
Restricted stock$23,381 1.8 years
Performance share awards22,830 1.8 years
Total unrecognized stock-based compensation expense$46,211 1.8 years
Schedule of Aggregate Intrinsic Value of Stock Options
The aggregate intrinsic value of stock options at March 31, 2023 was as follows (in thousands):
Intrinsic Value of Stock Options
Outstanding and exercisable$2,325 
Exercised during the nine months ended March 31, 202378